CPMV · Mosaic Immunoengineering Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $64.0K | $183.9K | $435.4K | $1.05M | $1.46M | - |
| SG&A | $552.1K | $695.8K | $964.3K | $1.58M | $2.05M | $996.0K |
| Total Operating Expenses | $616.1K | $879.7K | $1.40M | $2.63M | $3.50M | $996.0K |
| D&A | - | - | - | - | - | $488 |
| Operating Income | ($616.1K) | ($879.7K) | ($1.40M) | ($3.50M) | ($3.68M) | ($1.06M) |
| Interest Expense | $10.0K | $7.0K | - | - | - | - |
| Income Tax | $2.4K | $2.4K | $2.4K | $2.4K | $2.4K | $1.6K |
| Net Income | ($687.8K) | ($922.0K) | ($1.01M) | ($2.38M) | ($3.68M) | ($1.06M) |
| EPS - Basic | ($0.10) | ($0.13) | ($0.14) | ($0.33) | ($0.55) | $0.00 |
| EPS - Diluted | ($0.10) | ($0.13) | ($0.14) | ($0.33) | ($0.55) | $0.00 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.6K | $115.0K | $156.2K | $220.6K | $226.1K | $352.7K |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $132.8K | $134.9K | $118.5K | $133.5K | $113.5K | $86.0K |
| Current Assets | $19.9K | $141.6K | $179.5K | $261.3K | $269.5K | $457.8K |
| Total Assets | $19.9K | $141.6K | $179.5K | $261.3K | $269.5K | $457.8K |
| Current Liabilities | $6.03M | $5.54M | $4.73M | $3.92M | $2.33M | $880.3K |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $7.50M | $6.93M | $6.05M | $5.15M | $3.07M | $880.3K |
| Stockholders' Equity | ($7.48M) | ($6.79M) | ($5.87M) | ($4.88M) | ($2.80M) | ($422.5K) |
| Retained Earnings | ($9.53M) | ($8.84M) | ($7.92M) | ($6.91M) | ($4.53M) | ($842.8K) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($111.4K) | ($241.2K) | ($497.5K) | ($690.1K) | ($679.2K) | ($986.8K) |
| Investing Cash Flow | - | $0 | $433.0K | $343.0K | $27.6K | $750.0K |
| Financing Cash Flow | $0 | $200.0K | $0 | $341.6K | $525.0K | - |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -3459.6% | -651.1% | -561.6% | -911.2% | -1367.2% | -231.7% |
| Return on equity | 9.2% | 13.6% | 17.2% | 48.7% | 131.6% | 251.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.00 | 0.03 | 0.04 | 0.07 | 0.12 | 0.52 |
| Quick ratio | 0.00 | 0.03 | 0.04 | 0.07 | 0.12 | 0.52 |
| Cash ratio | 0.00 | 0.02 | 0.03 | 0.06 | 0.10 | 0.40 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -61.6x | -126.5x | - | - | - | - |
| Equity multiplier | -0.00 | -0.02 | -0.03 | -0.05 | -0.10 | -1.08 |
| Liabilities / Assets | 377.02 | 48.94 | 33.70 | 19.70 | 11.39 | 1.92 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 30.0% | 37.2% | 60.0% | 4.9% | -247.7% | -32.9% |
| Net income growth (YoY) | 25.4% | 8.6% | 57.7% | 35.4% | -247.4% | -32.8% |
| EPS growth (YoY) | 23.1% | 7.1% | 57.6% | 40.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -10.1% | -15.6% | -20.2% | -74.5% | -562.4% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Mosaic ImmunoEngineering Inc. against the 5 most active filers in the same SIC group.